|
1
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 28:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guren MG: The global challenge of
colorectal cancer. Lancet Gastroenterol Hepatol. 4:894–895. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li D: Diabetes and pancreatic cancer. Mol
Carcinog. 51:64–74. 2011. View
Article : Google Scholar
|
|
5
|
Yadav D and Lowenfels AB: The epidemiology
of pancreatitis and pancreatic cancer. Gastroenterology.
144:1252–1261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ansari D, Tingstedt B, Andersson B,
Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M
and Andersson R: Pancreatic cancer: Yesterday, today and tomorrow.
Future Oncol. 12:1929–1246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maisonneuve P: Epidemiology and burden of
pancreatic cancer. Presse Med. 48:e113–e123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poruk KE, Firpo MA and Mulvihill SJ:
Screening for pancreatic cancer. Ann Surg. 257:17–26. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Capasso M, Franceschi M, Rodriguez-Castro
KI, Crafa P, Cambiè G, Miraglia C, Barchi A, Nouvenne A, Leandro G,
Meschi T, et al: Epidemiology and risk factors of pancreatic
cancer. Acta Biomed. 89:141–146. 2018.PubMed/NCBI
|
|
12
|
Vilaverde F, Reis A, Rodrigues P, Carvalho
A and Scigliano H: Adult pancreatoblastoma-case report and review
of literature. J Radiol Case Rep. 31:28–38. 2016.PubMed/NCBI
|
|
13
|
Geurts JL: Inherited syndromes involving
pancreatic neuroendocrine tumors. J Gastrointest Oncol. 11:559–566.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Q, Chen S, Zeng L, Chen Y, Lian G,
Qian C, Li J, Xie R and Huang KH: New developments in the early
diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol.
11:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kolodecik T, Shugrue C, Ashat M and
Thrower EC: Risk factors for pancreatic cancer: Underlying
mechanisms and potential targets. Front Physiol. 16:4152014.
|
|
17
|
Haeberle L and Esposito I: Pathology of
pancreatic cancer. Transl Gastroenterol Hepatol. 27:502019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pereira NP and Corrêa JR: Pancreatic
cancer: Treatment approaches and trends. J Cancer Metastasis Treat.
4:302018. View Article : Google Scholar
|
|
19
|
Berardi R, Mandolesi A, Pellei C,
Maccaroni E, Onofri A, Lucarelli A, Biagetti S, Alfonsi S,
Caramanti M, Savini A, et al: Prognostic factors in pancreatic
cancer: The role of perineural, vascular and lymphatic invasion and
of Ca19-9. J Gastroint Dig Syst. 3:1342013.
|
|
20
|
Delpu Y, Hanoun N, Lulka H, Sicard F,
Selves J, Buscail L, Torrisani J and Cordelier P: Genetic and
epigenetic alterations in pancreatic carcinogenesis. Curr Genomics.
12:15–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andrén-Sandberg A: Non-pancreatic cancer
tumors in the pancreatic region. N Am J Med Sci. 3:55–62. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaur S, Baine MJ, Jain M, Sasson AR and
Batra SK: Early diagnosis of pancreatic cancer: Challenges and new
developments. Biomark Med. 6:597–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khan MA, Azim S, Zubair H, Bhardwaj A,
Patel GK, Khushman M, Singh S and Singh AP: Molecular drivers of
pancreatic cancer pathogenesis: Looking inward to move forward. Int
J Mol Sci. 6:7792017. View Article : Google Scholar
|
|
24
|
Hruban RH and Fukushima N: Pancreatic
adenocarcinoma: Update on the surgical pathology of carcinomas of
ductal origin and PanINs. Mod Pathol. 20 (Suppl 1):S61–S70. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang Y, Yao Q, Chen Z, Xiang J, William
FE, Gibbs RA and Chen C: Genetic and molecular alterations in
pancreatic cancer: Implications for personalized medicine. Med Sci
Monit. 31:916–926. 2013.PubMed/NCBI
|
|
26
|
Visani M, Acquaviva G, Leo AD, Sanza V,
Merlo L, Maloberti T, Brandes AA, Franceschi E, Battista MD,
Masetti M, et al: Molecular alterations in pancreatic tumors. World
J Gastroenterol. 7:2710–2726. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vernucci E, Abrego J, Gunda V, Shukla SK,
Dasgupta A, Rai V, Chaika N, Buettner K, Illies A, Yu F, et al:
Metabolic alterations in pancreatic cancer progression. Cancers
(Basel). 18:22019. View Article : Google Scholar
|
|
28
|
Gil YR, Sánchez PJ, Velasco RM, García AG
and Lobo VJ: Molecular alterations in pancreatic cancer: Transfer
to the clinic. Int J Mol Sci. 19:20772021.
|
|
29
|
Pandol S, Edderkaoui M, Gukovsky I, Lugea
A and Gukovskaya A: Desmoplasia of pancreatic ductal
adenocarcinoma. Clin Gastroenterol Hepatol. 7 (Suppl 11):S44–S47.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Merika EE, Syrigos KN and Saif MW:
Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol
Res Pract. 2012:7817652012.PubMed/NCBI
|
|
31
|
Annese T, Tamma R, Ruggieri S and Ribatti
D: Angiogenesis in pancreatic cancer: Pre-clinical and clinical
studies. Cancers (Basel). 18:3812019. View Article : Google Scholar
|
|
32
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao
HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic
cancer: Current research status and clinical implications.
Angiogenesis. 22:15–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng S, Pöttler M, Lan B, Grützmann R,
Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. Int J
Mol Sci. 11:45042019. View Article : Google Scholar
|
|
34
|
Grasso C, Jansen G and Giovannetti E: Drug
resistance in pancreatic cancer: Impact of altered energy
metabolism. Crit Rev Oncol Hematol. 114:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang S, Huang S and Sun YL:
Epithelial-mesenchymal transition in pancreatic cancer: A review.
Biomed Res Int. 2017:26461482017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Safa AR: Epithelial-mesenchymal
transition: A hallmark in pancreatic cancer stem cell migration,
metastasis formation, and drug resistance. J Cancer Metastasis
Treat. 6:362020.
|
|
38
|
Miura F, Takada T, Amano H, Yoshida M,
Furui S and Takeshita K: Diagnosis of pancreatic cancer. HPB
(Oxford). 8:337–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Song SW, Cheng JF, Liu N and Zhao TH:
Diagnosis and treatment of pancreatic metastases in 22 patients: A
retrospective study. World J Surg Oncol. 25:2992014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nalankilli K, Kannuthurai S and Moss A: A
modern approach to ERCP: Maintaining efficacy while optimising
safety. Dig Endosc. 28 (Suppl 1):S70–S76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tryliskyy Y and Bryce GJ: Post-ERCP
pancreatitis: Pathophysiology, early identification and risk
stratification. Adv Clin Exp Med. 27:149–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dietrich CF and Christian J: Modern
ultrasound imaging of pancreatic tumors. Ultrasonography.
39:105–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gañán IM, Ríos LF, de Toledo LS, Mombila
ME and Mendoza LH: Estadificación mediante tomografía computarizada
del carcinoma de páncreas. Radiologia. 60:10–23. 2018.(In English,
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azzaz HE, Abdullah MS and Habib RM: Role
of multidetector computed tomography in evaluation of resectability
of pancreatic cancer. Egyptian J Radiol Nuclear Med. 52:1402021.
View Article : Google Scholar
|
|
45
|
Deng L, Ke X, He Z, Yang D, Gong H, Zhang
Y, Jing X, Yao J and Chen J: A MSLN-targeted multifunctional
nanoimmunoliposome for MRI and targeting therapy in pancreatic
cancer. Int J Nanomedicine. 7:5053–5065. 2012.PubMed/NCBI
|
|
46
|
Le K, Wang J, Zhang T, Guo Y, Chang H,
Wang S and Zhu B: Overexpression of mesothelin in pancreatic ductal
adenocarcinoma (PDAC). Int J Med Sci. 17:422–427. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jha P and Bijan B: PET/CT for pancreatic
malignancy: Potential and pitfalls. J Nucl Med Technol. 43:92–97.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bhutani MS, Koduru P, Joshi V, Saxena P,
Suzuki R, Irisawa A and Yamao K: The role of endoscopic ultrasound
in pancreatic cancer screening. Endosc Ultrasound. 5:8–16. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guijarro LG, Sanmartin-Salinas P,
Pérez-Cuevas E, Toledo-Lobo MV, Monserrat J, Zoullas S, Sáez MA,
Álvarez-Mon MA, Bujan J, Noguerales-Fraguas F, et al: Possible role
of IRS-4 in the origin of multifocal hepatocellular carcinoma.
Cancers (Basel). 23:25602021. View Article : Google Scholar
|
|
50
|
Majumder S, Chari ST and Ahlquist DA:
Molecular detection of pancreatic neoplasia: Current status and
future promise. World J Gastroenterol. 28:11387–11395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kato K, Kamada H, Fujimori T, Aritomo Y,
Ono M and Masaki T: Molecular biologic approach to the diagnosis of
pancreatic carcinoma using specimens obtained by EUS-guided fine
needle aspiration. Gastroenterol Res Pract. 2012:2435242012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hanada K, Minami T, Shimizu A, Fukuhara M,
Yano S, Sasaki K, Koda M, Sugiyama K, Yonehara S and Yanagisawa A:
Roles of ERCP in the early diagnosis of pancreatic cancer.
Diagnostics (Basel). 7:302019. View Article : Google Scholar
|
|
53
|
Bispo M, Marques S, Rio-Tinto R, Fidalgo P
and Devière J: The role of endoscopic ultrasound in pancreatic
cancer staging in the Era of neoadjuvant therapy and personalised
medicine. GE Port J Gastroenterol. 28:111–120. 2021.PubMed/NCBI
|
|
54
|
Sun B and Hu B: The role of intraductal
ultrasonography in pancreatobiliary diseases. Endosc Ultrasound.
5:291–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Puri R, Manrai M, Thandassery RB and
Alfadda AA: Endoscopic ultrasound in the diagnosis and management
of carcinoma pancreas. World J Gastrointest Endosc. 25:67–76. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yamashita Y, Kato J, Ueda K, Nakamura Y,
Kawaji Y, Abe H, Nuta J, Tamura T, Itonaga M, Yoshida T, et al:
Contrast-enhanced endoscopic ultrasonography for pancreatic tumors.
Biomed Res Int. 2015:4917822015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pentyala S, Whyard T, Pentyala S, Muller
J, Pfail J, Parmar S, Helguero CG and Khan S: Prostate cancer
markers: An update. Biomed Rep. 4:263–268. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gonssaud B, Goussot V, Berriolo-Riedinger
A, Saïtta-Aribau E, Coutant C, Cochet A, Fumoleau P and Riedinger
JM: Clinical value of CA 15-3 for detection of distant metastases
in newly diagnosed breast cancer. Ann Biol Clin (Paris). 1:421–429.
2017.PubMed/NCBI
|
|
59
|
Bottoni P and Scatena R: The role of CA
125 as tumor marker: Biochemical and clinical aspects. Adv Exp Med
Biol. 867:229–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Coelho R, Silva M, Rodrigues-Pinto E,
Cardoso H, Lopes S, Pereira P, Vilas-Boas F, Santos-Antunes J,
Costa-Maia J and Macedo G: CA 19-9 as a marker of survival and a
predictor of metastization in cholangiocarcinoma. GE Port J
Gastroenterol. 24:114–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Poruk KE, Gay DZ, Brown K, Mulvihill JD,
Boucher KM, Scaife CL, Firpo MA and Mulvihill SJ: The clinical
utility of CA 19-9 in pancreatic adenocarcinoma: Diagnostic and
prognostic updates. Curr Mol Med. 13:340–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu C, Deng S, Jin K, Gong Y, Cheng H, Fan
Z, Qian Y, Huang Q, Ni Q, Luo G and Yu X: Lewis antigen-negative
pancreatic cancer: An aggressive subgroup. Int J Oncol. 56:900–908.
2020.PubMed/NCBI
|
|
63
|
Salleh S, Thyagarajan A and Sahu RP:
Exploiting the relevance of CA 19-9 in pancreatic cancer. J Cancer
Metastasis Treat. 6:312020.
|
|
64
|
Amburn TL, Ginn M, Patel R, Pandalai PK,
Kim J and Cavnar MJ: Clinical utility of symptoms and serum
carbohydrate antigen (CA) 19-9 for detection of recurrence after
curative intent resection of periampullary arcinoma. JACS.
231:E122–E1123. 2020.
|
|
65
|
Pereira SP, Oldfield L, Ney A, Hart PA,
Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, et al:
Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol.
5:698–710. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Agrawal S: Potential prognostic biomarkers
in pancreatic juice of resectable pancreatic ductal adenocarcinoma.
World J Clin Oncol. 10:255–260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yip-Schneider MT, Soufi M, Carr RA, Flick
KF, Wu H, Colgate CL and Schmidt CM: Performance of candidate
urinary biomarkers for pancreatic cancer-correlation with
pancreatic cyst malignant progression? Am J Surg. 219:492–495.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lim JH, Park JS and Yoon DS: Preoperative
fecal elastase-1 is a useful prognostic marker following curative
resection of pancreatic cancer. HPB (Oxford). 19:388–395. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xu R, Xu Q, Huang G, Yin X, Zhu J, Peng Y
and Song J: Combined analysis of the aberrant epigenetic alteration
of pancreatic ductal adenocarcinoma. Biomed Res Int.
28:93798642019.PubMed/NCBI
|
|
70
|
Rückert F, Pilarsky C and Grützmann R:
Serum tumor markers in pancreatic cancer-recent discoveries.
Cancers (Basel). 2:1107–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang J, Wang Y, Zhao T, Li Y, Tian L,
Zhao J and Zhang J: Evaluation of serum MUC5AC in combination with
CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol.
7:312020. View Article : Google Scholar
|
|
72
|
Kim H, Kang KN, Shin YS, Byun Y, Han Y,
Kwon W, Kim CW and Jang JY: Biomarker panel for the diagnosis of
pancreatic ductal adenocarcinoma. Cancers (Basel). 1:14432020.
View Article : Google Scholar
|
|
73
|
Loosen SH, Neumann UP, Trautwein C,
Roderburg C and Luedde T: Current and future biomarkers for
pancreatic adenocarcinoma. Tumor Biol. 39:1010428317692232017.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lee HS, Jang CY, Kim SA, Park SB, Jung DE,
Kim BO, Kim HY, Chung MJ, Park JY, Bang S, et al: Combined use of
CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic
cancer. Sci Rep. 21:33832018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kim J, Bamlet WR, Oberg AL, Chaffee KG,
Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM and Zaret KS:
Detection of early pancreatic ductal adenocarcinoma with
thrombospondin-2 and CA19-9 blood markers. Sci Transl Med.
12:eaah55832017. View Article : Google Scholar
|
|
76
|
Jenkinson C, Elliott VL, Evans A, Oldfield
L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A,
Fourkala EO, Jacobs IJ, et al: Decreased serum thrombospondin-1
levels in pancreatic cancer patients up to 24 months prior to
clinical diagnosis: Association with diabetes mellitus. Clin Cancer
Res. 22:1734–1743. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Radon TP, Massat NJ, Jones R, Alrawashdeh
W, Dumartin L, Ennis D, Duffy SW, Kocher HM, Pereira SP, posthumous
LG, et al: Identification of a three-biomarker panel in urine for
early detection of pancreatic adenocarcinoma. Clin Cancer Res.
1:3512–3521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Benassai G, Quarto G, Perrotta S, Furino
E, Benassai GL, Amato B, Bianco T, Palma GD and Forestieri P:
Long-term survival after curative resection for pancreatic ductal
adenocarcinoma-surgical treatment. Int J Surg. 21 (Suppl 1):S1–S3.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Jeekel H: Prognostic factors following
curative resection for pancreatic adenocarcinoma. Ann Surg.
240:3842004. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Brunner M, Wu Z, Krautz C, Pilarsky C,
Grützmann R and Weber GF: Current clinical strategies of pancreatic
cancer treatment and open molecular questions. Int J Mol Sci.
13:45432019. View Article : Google Scholar
|
|
81
|
Ho CK, Kleeff J, Friess H and Büchler MW:
Complications of pancreatic surgery. HPB (Oxford). 7:99–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Andren-Sandberg A: Complications of
pancreatic surgery. N Am J Med Sci. 3:531–535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Liu M, Ji S, Xu W, Liu W, Qin Y, Hu Q, Sun
Q, Zhang Z, Yu X and Xu X: Laparoscopic pancreaticoduodenectomy:
Are the best times coming? World J Surg Oncol. 10:812019.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhu R, Cao Z, Qiu J and Zhang T: Minimally
invasive pancreatic surgery: An upward spiral. Laparoscopic,
Endoscopic and Robotic Surgery. 3:29–33. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Magge D, Zureikat A, Hogg M and Zeh HJ
III: Minimally invasive approaches to pancreatic surgery. Surg
Oncol Clin N Am. 25:273–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Liu R, Wakabayashi G, Palanivelu C, Tsung
A, Yang K, Goh BK, Chong CC, Kang CM, Peng C, Kakiashvili E, et al:
International consensus statement on robotic pancreatic surgery.
Hepatobiliary Surg Nutr. 8:345–360. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rashid OM, Mullinax JE, Pimiento JM,
Meredith KL and Malafa MP: Robotic whipple procedure for pancreatic
cancer: The moffitt cancer center pathway. Cancer Control.
22:340–351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rehders A, Stoecklein NH, Güray A,
Riediger R, Alexander A and Knoefel WT: Vascular invasion in
pancreatic cancer: Tumor biology or tumor topography? Surgery. 152
(Suppl 1):S143–S151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zaky AM, Wolfgang CL, Weiss MJ, Javed AA,
Fishman EK and Zaheer A: Tumor-vessel relationships in pancreatic
ductal adenocarcinoma at multidetector CT: Different classification
systems and their influence on treatment planning. Radiographics.
37:93–112. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Dua MM, Tran TB, Klausner J, Hwa KJ,
Poultsides GA, Norton JA and Visser BC: Pancreatectomy with vein
reconstruction: Technique matters. HPB (Oxford). 17:824–831. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Delpero JR and Sauvanet A: Vascular
resection for pancreatic cancer: 2019 French recommendations based
on a literature review from 2008 to 6-2019. Front Oncol. 4:402020.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sgroi MD, Narayan RR, Lane JS, Demirjian
A, Kabutey NK, Fujitani RM and Imagawa DK: Vascular reconstruction
plays an important role in the treatment of pancreatic
adenocarcinoma. J Vasc Surg. 61:475–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Rebelo A, Michalski C, Ukkat J and Kleeff
J: Pancreatic cancer surgery with vascular resection: Current
concepts and perspectives. J Pancreatol. 2:1–5. 2019. View Article : Google Scholar
|
|
94
|
Perinel J and Adham M: Palliative therapy
in pancreatic cancer-palliative surgery. Transl Gastroenterol
Hepatol. 7:282019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Pencovich N, Orbach L, Lessing Y, Elazar
A, Barnes S, Berman P, Blachar A, Nachmany I and Sagie B:
Palliative bypass surgery for patients with advanced pancreatic
adenocarcinoma: Experience from a tertiary center. World J Surg
Oncol. 1:632020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Assfalg V, Hüser N, Michalski C, Gillen S,
Kleeff J and Friess H: Palliative interventional and surgical
therapy for unresectable pancreatic cancer. Cancers (Basel).
14:652–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Pezzilli R: Neuropathic pain in pancreatic
cancer: An update of the last five years. Gastroenterol Insights.
12:302–309. 2021. View Article : Google Scholar
|
|
98
|
Zhong W, Yu Z, Zeng JX, Lin Y, Yu T, Min
XH, Yuan YH and Chen QK: Celiac plexus block for treatment of pain
associated with pancreatic cancer: A meta-analysis. Pain Pract.
14:43–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Springfeld C, Jäger D, Büchler MW, Strobel
O, Hackert T, Palmer DH and Neoptolemos JP: Chemotherapy for
pancreatic cancer. Presse Med. 48:e159–e174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hajatdoost L, Sedaghat K, Walker EJ,
Thomas J and Kosari S: Chemotherapy in pancreatic cancer: A
systematic review. Medicina (Kaunas). 11:482018. View Article : Google Scholar
|
|
101
|
Marco MD, Cicilia RD, Macchini M, Nobili
E, Vecchiarelli S, Brandi G and Biasco G: Metastatic pancreatic
cancer: Is gemcitabine still the best standard treatment? (Review).
Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Martín AM, Hidalgo M, Alvarez R, Arrazubi
V, Martínez-Galán J, Salgado M, Macarulla T and Carrato A: From
first line to sequential treatment in the management of metastatic
pancreatic cancer. J Cancer. 30:1978–1988. 2018. View Article : Google Scholar
|
|
103
|
Conroy T, Hammel P, Hebbar M, Abdelghani
MB, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et
al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic
cancer. N Engl J Med. 20:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari N: Performance status assessment
by using ECOG (Eastern Cooperative Oncology Group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
25:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lee J, Lee JC, Gromski MA, Kim HW, Kim J,
Kim J and Hwang JH: Clinical outcomes of FOLFIRINOX in locally
advanced pancreatic cancer: A single center experience. Medicine
(Baltimore). 97:e135922018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY,
Chang HM, Lee SS, Park DH, Song TJ, Seo DW, et al: Efficacy and
safety of neoadjuvant FOLFIRINOX for borderline resectable
pancreatic adenocarcinoma: Improved efficacy compared with
gemcitabine-based regimen. Oncotarget. 11:46337–46347. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Tahara J, Shimizu K, Otsuka N, Akao J,
Takayama Y and Tokushige K: Gemcitabine plus nab-paclitaxel vs.
FOLFIRINOX for patients with advanced pancreatic cancer. Cancer
Chemother Pharmacol. 82:245–250. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ma P and Mumper RJ: Paclitaxel
nano-delivery systems: A comprehensive review. J Nanomed
Nanotechnol. 18:10001642013.PubMed/NCBI
|
|
109
|
Chatterjee M, Ben-Josef E, Robb R, Vedaie
M, Seum S, Thirumoorthy K, Palanichamy K, Harbrecht M, Chakravarti
A and Williams TM: Caveolae-mediated endocytosis is critical for
albumin cellular uptake and response to albumin-bound chemotherapy.
Cancer Res. 1:5925–5937. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yardley DA: Nab-paclitaxel mechanisms of
action and delivery. J Control Release. 28:365–372. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kang J, Hwang I, Yoo C, Kim KP, Jeong JH,
Chang HM, Lee SS, Park DH, Song TJ, Seo DW, et al: Nab-paclitaxel
plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy
for patients with metastatic pancreatic cancer: Retrospective
analysis. Invest New Drugs. 36:732–741. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Kim G: Nab-paclitaxel for the treatment of
pancreatic cancer. Cancer Manag Res. 16:85–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wolfe AR, Prabhakar D, Yildiz VO, Cloyd
JM, Dillhoff M, Abushahin L, Diaz DA, Miller ED, Chen W, Frankel
WL, et al: Neoadjuvant-modified FOLFIRINOX vs. nab-paclitaxel plus
gemcitabine for borderline resectable or locally advanced
pancreatic cancer patients who achieved surgical resection. Cancer
Med. 9:4711–4723. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sarabi M, Mais L, Oussaid N, Desseigne F,
Guibert P and Fouchardiere CD: Use of gemcitabine as a second-line
treatment following chemotherapy with folfirinox for metastatic
pancreatic adenocarcinoma. Oncol Lett. 13:4917–4924. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kordes M, Yu J, Malgerud O, Liljefors MG
and Löhr JM: Survival benefits of chemotherapy for patients with
advanced pancreatic cancer in a clinical real-world cohort. Cancers
(Basel). 7:13262019. View Article : Google Scholar
|
|
116
|
Oba A, Ho F, Bao QR, Al-Musawi MH,
Schulick RD and Chiaro MD: Neoadjuvant treatment in pancreatic
cancer. Front Oncol. 28:2452020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Versteijne E, Vogel JA, Besselink MG,
Busch OR, Wilmink JW, Daams JG, van Eijck CHJ, Koerkamp BG, Rasch
CR, van Tienhoven G, et al: Meta-analysis comparing upfront surgery
with neoadjuvant treatment in patients with resectable or
borderline resectable pancreatic cancer. Br J Surg. 105:946–958.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Seufferlein T and Ettrich TJ: Treatment of
pancreatic cancer-neoadjuvant treatment in resectable pancreatic
cancer (PDAC). Transl Gastroenterol Hepatol. 27:212019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Müller PC, Frey MC, Ruzza CM, Nickel F,
Jost C, Gwerder C, Hackert T, Z'graggen K and Kessler U:
Neoadjuvant chemotherapy in pancreatic cancer: An appraisal of the
current high-level evidence. Pharmacology. 106:143–153.
2021.PubMed/NCBI
|
|
120
|
Hall WA and Karyn A: Goodman: Radiation
therapy for pancreatic adenocarcinoma, a treatment option that must
be considered in the management of a devastating malignancy. Radiat
Oncol. 26:1142019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Tchelebi LT, Zaorsky NG, Rosenberg JC,
Sharma NK, Tuanquin LC, Mackley HB and Ellis RJ: Reducing the
toxicity of radiotherapy for pancreatic cancer with magnetic
resonance-guided radiotherapy. Toxicol Sci. 1:19–23. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Buwenge M, Macchia G, Arcelli A, Frakulli
R, Fuccio L, Guerri S, Grassi E, Cammelli S, Cellini F and Morganti
AG: Stereotactic radiotherapy of pancreatic cancer: A systematic
review on pain relief. J Pain Res. 4:2169–2178. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Palta M, Godfrey D, Goodman KA, Hoffe S,
Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N,
et al: Radiation therapy for pancreatic cancer: Executive summary
of an ASTRO clinical practice guideline. Pract Radiat Oncol.
9:322–332. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Shah AP, Strauss JB and Abrams RA: Review
and commentary on the role of radiation therapy in the adjuvant
management of pancreatic cancer. Am J Clin Oncol. 33:101–106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Jiang W, Haque W, Verma V, Butler EB and
Teh BS: Neoadjuvant stereotactic body radiation therapy for
nonmetastatic pancreatic adenocarcinoma. Acta Oncol. 58:1259–1266.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Glicksman RM, Chung H, Myrehaug S, Erler
D, Korol R, Karotki A, Taggar A and Ung YC: Stereotactic
radiotherapy for pancreatic cancer: A single-institution
experience. Cureus. 23:e106182020.PubMed/NCBI
|
|
127
|
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q,
Shi J and Hou Y: PD-L1 degradation pathway and immunotherapy for
cancer. Cell Death Dis. 6:9552020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei
J, Ren S and Zhou C: Tumor neoantigens: From basic research to
clinical applications. J Hematol Oncol. 6:932019. View Article : Google Scholar
|
|
129
|
Das M, Zhou X, Liu Y, Das A, Vincent BG,
Li J, Liu R and Huang L: Tumor neoantigen heterogeneity impacts
bystander immune inhibition of pancreatic cancer growth. Transl
Oncol. 13:1008562020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Chi J, Patel R, Rehman H, Goyal S and Saif
MW: Recent advances in immunotherapy for pancreatic cancer. J
Cancer Metastasis Treat. 6:432020.
|
|
131
|
Chen H, Yang G, Xiao J, Zheng L, You L and
Zhang T: Neoantigen-based immunotherapy in pancreatic ductal
adenocarcinoma (PDAC). Cancer Lett. 10:12–19. 2020. View Article : Google Scholar
|
|
132
|
Looi CK, Chung FFL, Leong CO, Wong SF,
Rosli R and Mai CW: Therapeutic challenges and current
immunomodulatory strategies in targeting the immunosuppressive
pancreatic tumor microenvironment. J Exp Clin Cancer Res.
15:1622019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Royal RE, Levy C, Turner K, Mathur A,
Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and
Rosenberg SA: Phase 2 trial of single agent ipilimumab
(Anti-CTLA-4) for locally advanced or metastatic pancreatic
adenocarcinoma. J Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 1:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Amin S, Baine M, Meza J, Alam M and Lin C:
The impact of immunotherapy on the survival of pancreatic
adenocarcinoma patients who do not receive definitive surgery of
the tumor. Clin Transl Radiat Oncol. 7:34–40. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Brouwer TP, Vahrmeijer AL and de Miranda
NF: Immunotherapy for pancreatic cancer: Chasing the light at the
end of the tunnel. Cell Oncol (Dordr). 44:261–278. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Krishnamoorthy M, Lenehan JG, Burton JP
and Vareki SM: Immunomodulation in pancreatic cancer. Cancers
(Basel). 12:33402020. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sideras K, Braat H, Kwekkeboom J, van
Eijck CH, Peppelenbosch MP, Sleijfer S and Bruno M: Role of the
immune system in pancreatic cancer progression and immune
modulating treatment strategies. Cancer Treat Rev. 40:513–522.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Amedei A, Niccolai E and Prisco D:
Pancreatic cancer: Role of the immune system in cancer progression
and vaccine-based immunotherapy. Hum Vaccin Immunother.
10:3354–3368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Luo W, Yang G, Luo W, Cao Z, Liu Y, Qiu J,
Chen G, You L, Zhao F, Zheng L and Zhang T: Novel therapeutic
strategies and perspectives for metastatic pancreatic cancer:
Vaccine therapy is more than just a theory. Cancer Cell Int.
4:662020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Akce M, Zaidi MY, Waller EK, El-Rayes BF
and Lesinski GB: The potential of CAR T cell therapy in pancreatic
cancer. Front Immunol. 25:21662018. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Penack O and Koenecke C: Complications
after CD19+ CAR T-cell therapy. Cancers (Basel). 19:34452020.
View Article : Google Scholar
|
|
143
|
Golan T, Hammel P, Reni M, Cutsem EV,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline brca-mutated metastatic
pancreatic cancer. N Engl J Med. 25:317–327. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Picozzi V, Alseidi A, Winter J, Pishvaian
M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, et
al: Gemcitabine/nab-paclitaxel with pamrevlumab: A novel drug
combination and trial design for the treatment of locally advanced
pancreatic cancer. ESMO Open. 5:e0006682020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Alistar A, Morris BB, Desnoyer R, Klepin
HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R
Jr, Topaloglu U, et al: Safety and tolerability of the
first-in-class agent CPI-613 in combination with modified
FOLFIRINOX in patients with metastatic pancreatic cancer: A
single-centre, open-label, dose-escalation, phase 1 trial. Lancet
Oncol. 18:770–778. 2017. View Article : Google Scholar : PubMed/NCBI
|
